Table 1.
Baseline* characteristics of RA patients in RISE EHR and MarketScan data according to the testing status for rheumatoid factor and anti-CCP antibody
| RISE EHR (n = 134,406) | MarketScan (n = 78,787) | |||||||
|---|---|---|---|---|---|---|---|---|
| Not tested | Tested, without results** | Tested, with results** | SMD | Not tested | Tested, without results** | Tested, with results ** | SMD | |
| N | 72,432 | 8710 | 53,264 | 46,676 | 29,925 | 2186 | ||
| Age | 62.5 (13.5) | 61.3 (14.0) | 60.7 (14.0) | 0.0877 | 56.82 (12.70) | 52.13 (11.54) | 54.04 (12.19) | 0.2572 |
| Female | 55,930 (77.2) | 6758 (77.6) | 41,365 (77.7) | 0.0225 | 36,376 (77.9) | 23,485 (78.5) | 1735 (79.4) | 0.0234 |
| Charlson Comorbidity Index | 0.0363 | 0.0973 | ||||||
| 1–2 | 68,170 (94.1) | 8118 (93.2) | 46,948 (93.2) | 31,615 (67.7) | 20,410 (68.2) | 1366 (62.5) | ||
| 3–4 | 3938 (5.4) | 561 (6.4) | 3334 (93.2) | 9351 (20.0) | 6330 (21.2) | 517 (23.7) | ||
| ≥ 5 | 324 (0.4) | 31 (0.4) | 282 (0.5) | 5710 (12.2) | 3185 (10.6) | 303 (13.9) | ||
| Comorbidities*** | ||||||||
| Cerebrovascular disease | 556 (0.8) | 54 (0.6) | 375 (0.7) | 0.0119 | 5081 (10.9) | 2847 (9.5) | 271 (12.4) | 0.0616 |
| Congestive heart failure | 364 (0.5) | 47 (0.5) | 258 (0.5) | 0.0052 | 2951 (6.3) | 1502 (5.0) | 148 (6.8) | 0.0496 |
| Constructive pulmonary disease | 2612 (3.6) | 332 (3.8) | 1856 (3.5) | 0.0116 | 13,155 (28.2) | 9010 (30.1) | 638 (29.2) | 0.0282 |
| Diabetes without complication | 3076 (4.2) | 438 (5.0) | 2961 (5.6) | 0.0406 | 5777 (12.4) | 4262 (14.2) | 366 (16.7) | 0.0827 |
| Diabetes with complication | 289 (0.4) | 28 (0.3) | 260 (0.5) | 0.0175 | 2774 (5.9) | 1643 (5.5) | 158 (7.2) | 0.0475 |
| Malignancy | 1302 (1.8) | 173 (2.0) | 954 (1.8) | 0.0096 | 3837 (8.2) | 2108 (7.0) | 172 (7.9) | 0.0295 |
| Myocardial infarction | 67 (0.1) | 7 (0.1) | 47 (0.1) | 0.0028 | 1559 (3.3) | 748 (2.5) | 61 (2.8) | 0.0333 |
| Mild liver disease | 957 (1.3) | 163 (1.9) | 1134 (2.1) | 0.0415 | 4673 (10.0) | 3762 (12.6) | 327 (15.0) | 0.1001 |
| Peptic ulcer disease | 345 (0.5) | 47 (0.5) | 284 (0.5) | 0.0059 | 406 (0.9) | 262 (0.9) | 26 (1.2) | 0.0211 |
| Peripheral vascular disease | 453 (0.6) | 72 (0.8) | 398 (0.7) | 0.0158 | 1360 (2.9) | 939 (3.1) | 79 (3.6) | 0.0263 |
| Stroke | 234 (0.3) | 18 (0.2) | 151 (0.3) | 0.0151 | 1479 (3.2) | 819 (2.7) | 85 (3.9) | 0.043 |
| Medication use, % | ||||||||
| Methotrexate | 39,177 (54.1) | 4567 (52.4) | 29,128 (54.7) | 0.0301 | 26,185 (56.1) | 17,789 (59.4) | 1371 (62.7) | 0.09 |
| Other csDMARDS | 28,950 (40.0) | 3927 (45.1) | 24,042 (45.1) | 0.0698 | 19,894 (42.6) | 14,915 (49.8) | 996 (45.6) | 0.0967 |
| TNFi biologics | 18,151 (25.1) | 1961 (22.5) | 11,443 (21.5) | 0.0565 | 19,030 (40.8) | 8204 (27.4) | 525 (24.0) | 0.2421 |
| Non-TNFi biologics | 6495 (9.0) | 663 (7.6) | 3662 (6.9) | 0.0517 | 6593 (14.1) | 2814 (9.4) | 183 (8.4) | 0.122 |
| Targeted synthetic DMARDs | 2694 (3.7) | 342 (3.9) | 1638 (3.1) | 0.0309 | 2048 (4.4) | 983 (3.3) | 48 (2.2) | 0.0824 |
| NSAIDs | 24,610 (34.0) | 3273 (37.6) | 20,631 (38.7) | 0.0660 | 20,925 (44.8) | 18,289 (61.1) | 1332 (60.9) | 0.2204 |
| Opioids | 14,177 (19.6) | 1799 (20.7) | 11,123 (20.9) | 0.0217 | 21,849 (46.8) | 16,795 (56.1) | 1197 (54.8) | 0.1247 |
| Glucocorticoid use | 26,889 (37.1) | 3552 (40.8) | 24,132 (45.3) | 0.1111 | 34,034 (72.9) | 25,335 (84.7) | 1852 (84.7) | 0.1947 |
| Seropositive by RF and/or CCP, % | N/A | N/A | 30,530 (57.3) | N/A | N/A | 1511 (69.1) | ||
| M05 diagnosis code (rather than M06), % | 46,084 (63.6) | 4753 (54.6) | 29,245 (54.9) | 0.1233 | 25,728 (55.1) | 15,584 (52.1) | 1226 (56.1) | 0.0536 |
SMD standardized mean difference, SMDs > 0.10 are potentially important; DMARD disease-modifying anti-rheumatic drug; TNFi tumor necrosis factor inhibitor; NSAID non-steroidal anti-inflammatory drugs. Baseline refers to the date of the 2nd ICD-10 diagnosis code for RA
**Tested with results means that the patient was tested for either or both RF and anti-CCP antibody (e.g., based on billing claims for the relevant lab tests) and had a valid lab result available; tested without results means that they were tested, but results were not available in the dataset; ***as measured in the Charlson Comorbidity Index